Denosumab, a fully
human monoclonal antibody drug, binds specifically to RANK - ligand (RANKL) and inhibits osteoclast - induced bone resorption by preventing the binding of RANKL to RANK.
Not exact matches
«Development Trends for
Human Monoclonal Antibody Therapeutics,» by Aaron L. Nelson, Eugen Dhimolea and Janice M. Reichert, Nature Reviews
Drug Discovery, October 2010.
Post says the study is a new take on
monoclonal antibody drugs that have been used in
humans.